Ares Capital Corporation (ARCC) - 2018 Annual Report Summary
Business Context and Reporting Period
Company: Ares Capital Corporation (ARCC)
Filing Type: Form 10-K
Reporting Period: Fiscal year ended December 31, 2018
Business Model: Ares Capital is a closed-end, non-diversified management investment company regulated as a Business Development Company (BDC). It is externally managed by Ares Capital Management LLC, a subsidiary of Ares Management Corporation. The company's objective is to generate current income and capital appreciation primarily through first and second lien senior secured loans, mezzanine debt, and equity investments in U.S. middle-market companies.
Key Financial Metrics
| Metric | 2018 | 2017 |
|---|---|---|
| Total Investment Income | $1,337 million | $1,160 million |
| Net Investment Income | $694 million | $511 million |
| Net Increase in Stockholders' Equity (Operations) | $858 million | $667 million |
| Net Asset Value (NAV) per Share | $17.12 | $16.65 |
| Total Assets | $12,895 million | $12,347 million |
| Total Debt (Principal Amount) | $5,297 million | $4,943 million |
| Weighted Average Yield (Total Portfolio) | 9.0% | 8.7% |
| Asset Coverage Ratio | 236% | 236% |
Material Changes vs. Prior Period
- Revenue Growth: Total investment income increased 15.3% to $1.337 billion, driven by a larger average portfolio size ($11.9 billion vs. $11.4 billion) and a higher weighted average yield (9.0% vs. 8.5%) due to rising LIBOR rates.
- Profitability: Net investment income rose 35.8% to $694 million. This increase was supported by higher investment income and a $40 million waiver of income-based fees by the investment adviser (compared to $30 million in 2017).
- Realized Gains: Net realized gains on investments surged to $406 million in 2018, compared to $44 million in 2017. A significant portion ($324 million) was attributed to the exit of Alcami Holdings, LLC.
- Unrealized Losses: The company recorded net unrealized losses of $255 million in 2018, reversing the $136 million unrealized gains recorded in 2017. This was primarily due to valuation adjustments on specific portfolio companies.
- Debt Levels: Total debt principal increased by approximately $354 million to $5.297 billion, reflecting continued leverage to fund investment activities.
Guidance, Outlook, and Risks
Management Commentary & Outlook: Management highlighted a strong investment pipeline and backlog of approximately $1.435 billion as of February 7, 2019. The company continues to focus on self-originated investments in the middle market. In February 2019, the Board authorized an increase in the stock repurchase program to $500 million (from $300 million) and extended the expiration date to February 28, 2020.
Regulatory Changes: The Board approved the application of modified asset coverage requirements under the Small Business Credit Availability Act (SBCAA). Effective June 21, 2019 (unless earlier stockholder approval is obtained), the asset coverage requirement will reduce from 200% to 150%, allowing the company to increase leverage. Concurrently, the base management fee on assets financed with leverage over 1.0x will be reduced from 1.5% to 1.0%.
Risks and Contingencies:
- Interest Rate Risk: The portfolio is sensitive to interest rate fluctuations. Approximately 85% of investments bear variable rates, while debt obligations include both fixed and variable rates. Rising rates generally benefit net investment income due to interest rate floors on assets.
- Valuation Uncertainty: A significant portion of the portfolio consists of private investments without readily available market quotations, requiring fair value determination by the Board, which introduces estimation risk.
- Liquidity: As a BDC, the company must distribute at least 90% of taxable income to maintain RIC status, limiting the ability to retain earnings for growth. Liquidity is dependent on access to capital markets and cash flows from operations.
- Legal Proceedings: The company is a defendant in a lawsuit involving DSI Renal Holdings LLC, where the plaintiff seeks approximately $117 million in damages. Management believes the claims are without merit.
Key Facts for Investor Verification
- Fee Waiver Expiration: Verify the impact of the income-based fee waiver expiring after the third quarter of 2019, which will increase future expense ratios.
- Asset Coverage Change: Monitor the implementation of the reduced 150% asset coverage ratio in June 2019 and its effect on leverage capacity and risk profile.
- Convertible Notes Maturity: Note the maturity of the $300 million 2019 Convertible Notes in January 2019 (subsequently repaid) and the conversion terms of the $388 million 2022 Convertible Notes.
- Portfolio Concentration: Review the top 10 portfolio companies, which represented a significant portion of the portfolio at fair value, to assess concentration risk.
- Stock Price vs. NAV: As of February 7, 2019, the stock traded at a discount of approximately 3.4% to NAV ($16.53 vs. $17.12).